An eyecare foundation model for clinical assistance: a randomized controlled trial
- PMID: 40877476
- DOI: 10.1038/s41591-025-03900-7
An eyecare foundation model for clinical assistance: a randomized controlled trial
Abstract
In the context of an increasing need for clinical assessments of foundation models, we developed EyeFM, a multimodal vision-language eyecare copilot, and conducted a multifaceted evaluation, including retrospective validations, multicountry efficacy validation as a clinical copilot and a double-masked randomized controlled trial (RCT). EyeFM was pretrained on 14.5 million ocular images from five imaging modalities paired with clinical texts from global, multiethnic datasets. Efficacy validation invited 44 ophthalmologists across North America, Europe, Asia and Africa in primary and specialty care settings, highlighting its utility as a clinical copilot. The RCT-a parallel, single-center, double-masked study-assessed EyeFM as a clinical copilot in retinal disease screening among a high-risk population in China. A total of 668 participants (mean age 57.5 years, 79.5% male) were randomized to 16 ophthalmologists, equally allocated into intervention (with EyeFM copilot) and control (standard care) groups. The primary endpoint indicated that ophthalmologists with EyeFM copilot achieved higher correct diagnostic rate (92.2% versus 75.4%, P < 0.001) and referral rate (92.2% versus 80.5%, P < 0.001). Secondary outcome indicated improved standardization score of clinical reports (median 33 versus 37, P < 0.001). Participant satisfaction with the screening was similar between groups, whereas the intervention group demonstrated higher compliance with self-management (70.1% versus 49.1%, P < 0.001) and referral suggestions (33.7% versus 20.2%, P < 0.001) at follow-up. Post-deployment evaluations indicated strong user acceptance. Our study provided evidence that implementing EyeFM copilot can improve the performance of ophthalmologists and the outcome of patients. Chinese Clinical Trial Registry registration: ChiCTR2500095518 .
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: Y.J. is a patent holder of Optovue/Visionix, Inc., Optos plc and Genentech, Inc. She receives financial support from Genentech, Inc., and she receives financial compensation from Optovue/Visionix, Inc. and Genentech, Inc. P.A.K. is a co-founder of Cascader Ltd., has acted as a consultant for Retina Consultants of America, Roche, Boehringer Ingleheim and Bitfount and is an equity owner in Big Picture Medical. He has received speaker fees from Zeiss, Thea, Apellis and Roche. He has received travel support from Bayer and Roche. He has attended advisory boards for Topcon, Bayer, Boehringer Ingleheim and Roche. T.Y.W. is a consultant for AbbVie Pte Ltd., Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Zeiss, Genentech, Iveric Bio, Novartis, Opthea Limited, Plano, Quaerite Biopharm Research Ltd., Roche, Sanofi and Shanghai Henlius. He is an inventor, holds patents and is a co-founder of start-up companies EyRiS and Visre, which have interests in, and develop digital solutions for, eye diseases. All potential conflicts of interests for consultancy, advisory boards and positions in the start-up companies and financial renumeration, if any, are managed by institutional policies under SingHealth and Tsinghua University. The other authors declare no competing interests.
References
Grants and funding
LinkOut - more resources
Full Text Sources